UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5915 - 5915
Journal Article
Biosensors & bioelectronics, ISSN 0956-5663, 12/2016, Volume 86, pp. 879 - 884
6-Thioguanine | Dasatinib | Pt/MWCNTs | 6-Mercaptopurine | Sensor | Ionic liquid | Physical Sciences | Chemistry | Nanoscience & Nanotechnology | Life Sciences & Biomedicine | Electrochemistry | Science & Technology - Other Topics | Biophysics | Chemistry, Analytical | Biotechnology & Applied Microbiology | Science & Technology | Humans | Imidazoles - chemistry | Thioguanine - urine | Equipment Design | Mercaptopurine - chemistry | Mercaptopurine - urine | Platinum - chemistry | Conductometry - instrumentation | Sensitivity and Specificity | Dasatinib - urine | Dasatinib - analysis | Metal Nanoparticles - ultrastructure | Reproducibility of Results | Thioguanine - chemistry | Metal Nanoparticles - chemistry | Nanotubes, Carbon - ultrastructure | Antineoplastic Agents - analysis | Complex Mixtures - chemistry | Dasatinib - chemistry | Antineoplastic Agents - chemistry | Antineoplastic Agents - urine | Nanotubes, Carbon - chemistry | Complex Mixtures - analysis | Mercaptopurine - analysis | Thioguanine - analysis | Equipment Failure Analysis | Phosphates | Sensors | Thioguanine | Polyols | Analysis | Mercaptopurine | Fluorides | Index Medicus | Electrodes | Drugs | Human body | Nanostructure | Biosensors | Carbon
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 07/2016, Volume 34, Issue 20, pp. 2333 - 2340
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Dasatinib - therapeutic use | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Imatinib Mesylate - therapeutic use | Imatinib Mesylate - adverse effects | Adult | Aged | Dasatinib - adverse effects | Mutation | Leukemia, Myeloid, Chronic-Phase - genetics | Index Medicus | Hema7 | Bios3 | To19 | ORIGINAL REPORTS
Journal Article
Biological & pharmaceutical bulletin, ISSN 0918-6158, 2015, Volume 38, Issue 5, pp. 645 - 654
imatinib | dasatinib | nilotinib | therapeutic drug monitoring | Nilotinib | Therapeutic drug monitoring | Dasatinib | Imatinib | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pyrimidines - administration & dosage | Pyrimidines - blood | Humans | Dasatinib - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein Kinase Inhibitors - blood | Dasatinib - blood | Protein Kinase Inhibitors - administration & dosage | Imatinib Mesylate - therapeutic use | Dasatinib - administration & dosage | Imatinib Mesylate - blood | Antineoplastic Agents - adverse effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Imatinib Mesylate - adverse effects | Imatinib Mesylate - administration & dosage | Pyrimidines - adverse effects | Antineoplastic Agents - blood | Dasatinib - adverse effects | Drug Monitoring | Index Medicus
Journal Article
American journal of hematology, ISSN 0361-8609, 09/2016, Volume 91, Issue 9, pp. 869 - 874
Life Sciences & Biomedicine | Hematology | Science & Technology | Pancytopenia - chemically induced | Follow-Up Studies | Pleural Effusion - chemically induced | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Dasatinib - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Treatment Outcome | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Chronic-Phase - complications | Imatinib Mesylate | Disease-Free Survival | Dasatinib - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Patient Safety | Dasatinib - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Antimitotic agents | Tyrosine | Oncology, Experimental | Clinical trials | Research | Chronic myeloid leukemia | Antineoplastic agents | Pulmonary hypertension | Cancer | Hypertension | Prescription drugs | Drug dosages | Leukemia | Index Medicus
Journal Article
Journal of controlled release, ISSN 0168-3659, 07/2017, Volume 258, pp. 43 - 55
Prodrug micelles | Dasatinib | Redox responsive | Co-delivery | Doxorubicin | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Prodrugs - administration & dosage | Doxorubicin - therapeutic use | Humans | Dasatinib - pharmacokinetics | Delayed-Action Preparations - chemistry | Polyethylene Glycols - chemistry | Drug Delivery Systems | Micelles | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Oxidation-Reduction | Dasatinib - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Animals | Dasatinib - administration & dosage | Antibiotics, Antineoplastic - therapeutic use | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice, Inbred BALB C | Prodrugs - therapeutic use | Neoplasms - pathology | Ethylene glycol | Anthracyclines | Chemotherapy | Polymers | Analysis | Cancer | Tyrosine | Medical colleges | Pharmacogenetics | Pharmacy | Physiological aspects | Drugstores | Index Medicus | co-delivery | dasatinib | doxorubicin | prodrug micelles | redox responsive
Journal Article
Cancer, ISSN 0008-543X, 03/2016, Volume 122, Issue 6, pp. 868 - 874
adaptive | dasatinib | phase 2 | sarcoma | Bayesian | Choi | Life Sciences & Biomedicine | Oncology | Science & Technology | Osteosarcoma - drug therapy | Humans | Middle Aged | Rhabdomyosarcoma - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Neoplasm Grading | Antineoplastic Agents - adverse effects | Adult | Female | Rhabdomyosarcoma - drug therapy | Drug Administration Schedule | Leiomyosarcoma - pathology | Dasatinib - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Sarcoma - drug therapy | Sarcoma - pathology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Dasatinib - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Bayes Theorem | Leiomyosarcoma - drug therapy | Aged | Dasatinib - adverse effects | Osteosarcoma - pathology | Index Medicus | Abridged Index Medicus
Journal Article
Science (American Association for the Advancement of Science), ISSN 0036-8075, 07/2019, Volume 365, Issue 6448, p. 41
Journal Article
European journal of clinical pharmacology, ISSN 0031-6970, 2/2016, Volume 72, Issue 2, pp. 185 - 193
Dasatinib | Pharmacodynamics | Biomedicine | Half maximal inhibitory concentration | Phamacokinetics | Pharmacology/Toxicology | Molecular response | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Leukocytes, Mononuclear - metabolism | Antigens, CD34 - metabolism | Oncogene Protein v-crk - antagonists & inhibitors | Humans | Middle Aged | Oncogene Protein v-crk - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Leukocytes, Mononuclear - drug effects | Dasatinib - therapeutic use | Treatment Outcome | Dasatinib - pharmacology | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Phosphotransferases | Analysis | Chronic myeloid leukemia | Pharmacology | Kinetics | Drug therapy | Leukemia | Chronic illnesses | Index Medicus
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3207 - 3218
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Reactive Oxygen Species - metabolism | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | E-Selectin - blood | Male | Hypertension, Pulmonary - chemically induced | Hypoxia - metabolism | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adult | Female | Intercellular Adhesion Molecule-1 - blood | Antineoplastic Agents - pharmacology | Genetic Predisposition to Disease | Imatinib Mesylate - pharmacology | Cells, Cultured | Rats | Mitochondria - metabolism | Vascular Cell Adhesion Molecule-1 - blood | Dasatinib - pharmacology | Animals | Lung - drug effects | Dasatinib - adverse effects | Hemodynamics | Lung - blood supply | Apoptosis | Dasatinib | Research | Health aspects | Pulmonary hypertension | Risk factors | Scholarships & fellowships | Toxicity | Mortality | Rodents | Leukemia | Hypoxia | Grants | Laboratory animals | Experiments | Drug dosages | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cellular Biology | Cardiology and cardiovascular system | Pulmonology and respiratory tract
Journal Article
EBioMedicine, ISSN 2352-3964, 09/2019, Volume 47, pp. 446 - 456
Dasatinib | Senolytics | Senescence-associated secretory phenotype | Cellular senescence | Quercetin | Diabetic kidney disease | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Immunohistochemistry | Humans | Middle Aged | Cellular Senescence - drug effects | Diabetic Nephropathies - drug therapy | Male | Adipocytes - drug effects | Diabetic Nephropathies - diagnosis | Kidney Function Tests | Adipose Tissue - metabolism | Female | Drug Therapy, Combination | Quercetin - therapeutic use | Diabetic Nephropathies - metabolism | Dasatinib - therapeutic use | Dasatinib - pharmacology | Macrophages - metabolism | Quercetin - pharmacology | Biopsy | Adipocytes - metabolism | Biomarkers | Macrophages - drug effects | Aged | Adipose Tissue - drug effects | Clinical Trials, Phase I as Topic | Index Medicus
Journal Article